
Overview
Farmak International operates in the pharmaceutical sector, offering prescription medicines, over-the-counter medicines, dietary supplements and medical devices. Its communicated medicinal products include Dutilox and Levosimendan Farmak, and the company also participates in medical and pharmaceutical conferences.
Financials
Revenue history (in m)
From the notes
| Profit allocation | Loss covered | |
| Loans and borrowings | $2,048,521 | |
| Capital expenditure | $548,985 | |
| Planned capital expenditure (next year) | $77,875 | |
| Foreign sales | 64.62% of revenue ($62,806,880) | |
| Revenue structure | Sprzedaż produktów |
Filing timeliness
3 of 6 financial statements were filed late (the longest delay 153 days for 2021). All were audited by a statutory auditor.
- 202514/07/2026
- 202415/07/2025
- 202324/09/2024
- 202227/09/2023
- 202115/12/2022
- 202013/10/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.
Results vs industry
News

Update of product information for the medicinal product Dutilox

Information regarding the medicinal product Dutilox

Communication to healthcare professionals dated 06-08-2026

Statement of Farmak International Poland regarding the drug Levosimendan

Announcement of a change of the company's CEO

Farmak International took part as a partner in the Slawex 2025 National Pharmaceutical Conference
Industry
Websites
The sites target these markets: United Kingdom.
- farmakinternational.plFarmak International Sp. z o.o.JoomlaGoogle AnalyticsGoogle Tag ManagerLLiteSpeed
- pikopil.plStrona głównaJoomlaGoogle AnalyticsGoogle Tag ManagerLLiteSpeed
Public procurement
No recorded participation in tenders.
Farmak International has been a party to 2 cases before the National Appeal Chamber (since 2024).
| Date | Subject of dispute | Outcome | Other party | |
|---|---|---|---|---|
| Mar 18, 2024 | Order | – | Wojewódzki Szpital Specjalistyczny w Olsztynie | |
| Feb 2, 2024 | Judgment | Upheld | Zespół Opieki Zdrowotnej w Bolesławcu |
Trademarks
The company holds 109 active trademarks registered with the Polish Patent Office. 2 applications are pending. 20 marks have expired or were not registered. The first mark was filed in 2005.
| Mark | Protected until | |
|---|---|---|
| ASIL (word) | Nov 28, 2035 | |
| SIDAB (word) | Mar 13, 2035 | |
| MIGRAMOL (word) | Mar 13, 2035 | |
| Septogard plus | Mar 13, 2035 | |
| REGUBLO (word) | Mar 13, 2035 |
Authorized Representatives
Manner of representation
If the management board is a multi-member management board, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.
Supervisory board
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Farmak Group Limited | 53,745 | $7,258,914.10 | 100% |
Beneficial owners
| Person | Rights |
|---|---|
Sanctions and PEP
Sanctions
No matches (EU, UN, US, UK, MSWiA, World Bank)
PEP
No matches
Bank accounts
Registered as a VAT taxpayer on 2003-12-31.
81 1050 1461 1000 0024 0451 3232
06 1050 1461 1000 0023 5664 8283
84 1050 1461 1000 0024 0451 3372
Debt
No entries in the National Debtors Register (KRZ).
Real estate
| Type | Amount |
|---|---|
Buildings and premises | PLN 166.2KPLN 166,153 |
MSiG notices
| Publication date | Event | |
|---|---|---|
| Feb 4, 2025 | Merger plan |
Public aid
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jul 17, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $897.5K$897,482 | Polski Fundusz Rozwoju S.A. |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Adamed Pharma S.A. | $541,927,181.76 | adamed.com.pl | ||
| Aflofarm Farmacja Polska sp. z o.o. | $302,019,142.07 | aflofarm.pl | ||
| Biofarm sp. z o.o. | $143,422,260.45 | biofarm.pl | ||
| Zentiva Polska sp. z o.o. | $134,295,523.17 | zentiva.pl | ||
| Przedsiębiorstwo Produkcji Farmaceutycznej Hasco - Lek S.A. | $119,621,017.71 | hasco-lek.pl | ||
| Synoptis Pharma sp. z o.o. | $79,311,000.88 | synoptispharma.pl | ||
| Polfarmex S.A. | $73,543,379.32 | polfarmex.pl | ||
| SUN-Farm sp. z o.o. | $51,063,341.52 | sunfarm.pl | ||
| Tactica Pharmaceuticals sp. z o.o. | $28,095,609.42 | tactica.pl | ||
| Aristo Pharma sp. z o.o. | $22,775,627.72 | aristo-pharma.pl |
Change history
| Date | Event | |
|---|---|---|
| 2025-04-01 | Share capital increase (26,872,000.00 PLN → 26,872,500.00 PLN) | |
| 2025-04-01 | Name change ("symphar" → Farmak International) | |
| 2017-03-16 | Address change (Włoska 1, 00-777, Warszawa → Ul. Koszykowa 65, 00-667, Warszawa) | |
| 2015-07-23 | PKD change (Removed: 9 codes) | |
| 2013-02-21 | Share capital increase (21,429,000.00 PLN → 26,872,000.00 PLN) |
FAQ
Last updated: 2026-10-07